Skip to main content
AVTX
NASDAQ Life Sciences

Q3 Loss Narrower Than Expected as Avalo Beats Consensus by $8M

Tom Rudovsky · Reported by Reuters
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$6.91
Mkt Cap
$379.164M
52W Low
$6.53
52W High
$24.27
52W Position info
5.8% above low
Off High info
72% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

AVTX is trading near its 52-week low of $6.53 (5.8% above the low).

Summary

Avalo posted a Q3 net loss of $18.95M, well below the $27.20M consensus from nine analysts, a clear beat. Operating expenses still rose to $23.40M on higher manufacturing spend for AVTX-010 and abdakibart plus higher stock-based compensation and personnel costs. The company says its cash and investments fund operations into 2029, and it plans to start a Phase 3 trial of abdakibart in hidradenitis suppurativa in H1 2027, with an IND for AVTX-010 also targeted for H1 2027. This follows the 10-Q filed today and the $200M at-the-market program with Jefferies, which gives Avalo a large dilution tool alongside the improved loss figure. The key question is whether the narrower loss and 2029 runway hold up as the company ramps spending into late-stage development.

At the time of this announcement, AVTX was trading at $6.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $379.2M. The 52-week trading range was $6.53 to $24.27. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.


Price Chart

Share this article

Copied!

AVTX - Latest Insights

AVTX
Nov 05, 2026, 7:04 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $7.13
Real-time Price: $6.69 info
Change: -$0.440 (-6%) info
Market Cap: $390.306M info
AVTX
Aug 06, 2026, 7:03 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $18.69
Real-time Price: $6.69 info
Change: -$12.00 (-64%) info
Market Cap: $390.306M info
AVTX
Aug 06, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $18.69
Real-time Price: $6.69 info
Change: -$12.00 (-64%) info
Market Cap: $390.306M info
AVTX
Jun 23, 2026, 7:01 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $15.04
Real-time Price: $6.69 info
Change: -$8.35 (-56%) info
Market Cap: $390.306M info
AVTX
Jun 16, 2026, 7:18 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $14.80
Real-time Price: $6.69 info
Change: -$8.11 (-55%) info
Market Cap: $390.306M info